Navigation Links
Clusters of cooperating tumor-suppressor genes are found in large regions deleted in common cancers
Date:5/7/2012

Cold Spring Harbor, NY Scientists at Cold Spring Harbor Laboratory (CSHL) and Memorial Sloan-Kettering Cancer Center have amassed strong experimental evidence implying that commonly occurring large chromosomal deletions that are seen in many cancer types contain areas harboring multiple functionally linked genes whose loss, they posit, confers a survival advantage on growing tumors.

Looking closely at one large deletion -- a so-called copy-number alteration or CNA on 8p, the short arm of chromosome 8 -- in mouse models of human liver cancer, the team validated the presence of a number of genes which normally serve to suppress the formation of tumors, and demonstrated that they act together, and not singly, to suppress tumors. The 8p deletion is commonly seen in human liver cancer and in other epithelial cancers including those of the breast, colon and lung.

The research team, which was co-led by now-adjunct CSHL Professor Scott W. Lowe of Memorial Sloan-Kettering Cancer Center and CSHL Professor Michael Wigler, publishes their results online today in Proceedings of the National Academy of Sciences.

Their hypothesis about the relation between linked tumor suppressor genes in CNAs and tumor survival advantage, if validated in ongoing research, would significantly modify a popular theory of cancer genetics that has stood up since the 1970s. Called the "two-hit" hypothesis, it has helped to explain the behavior of certain cancer genes. All cancers arise from mutations in cancer genes that balance cellular proliferation and suppression of abnormal growth, resulting in out-of-control proliferation, cancer's hallmark.

Some cancers are the result of a single genetic "hit." An example is a single point mutation in the first human oncogene ever discovered, called RAS. It results in the production of an abnormal protein that drives cells to bypass growth checkpoints. The 2-hit hypothesis was proposed to explain aspects of a childhood eye cancer called retinoblastoma. Children with the inherited disease developed the disease early --- often in both eyes, whereas children who had the non-inherited, or sporadic form of the disease, developed it later and usually in one eye. It turned out that the inherited disease was caused by a recessive mutation in a single gene called RB1 but that the remaining, normal copy of the gene had to be lost in order for the disease process to begin. (We have two copies of most genes, one inherited from each parent.) The sporadic, non-inherited form of the disease required two hits of the RB1 gene, one of which was loss of a large region containing the gene.

This 2-hit model, which brilliantly explained retinoblastoma and some other cancers, "has also been used to explain what happens when all large chromosomal areas are lost in cancer something that happens quite frequently," notes Associate Professor Scott Powers, a CSHL geneticist and participant in the research published today.

"But the theory can't explain many of these large deletion events, for several reasons," Powers explains. "Most important, the deleted region often does not appear to contain a 'driver' tumor suppressor gene [like RB1] with a point mutation that would constitute the first 'hit.'" Lowe's lab at CSHL used the common 8p deletion to explore in mouse models of liver cancer what might be going on. Specifically, they asked a classic question in cancer: What selective advantage does the 8p deletion provide to the tumor?

In other words, when the 8p deletion occurs, how is a tumor's development aided? What new advantage do the affected cancer cells obtain?

The team found multiple genes within 8p and in adjacent areas of chromosome 8 that function cooperatively to inhibit the formation of tumors. They used RNA interference technology to show that the co-suppression of these linked sets of genes could "synergistically promote tumor growth."

These results "raise the possibility that large-scale genomic lesions can act through their effects on an opportunistic collection of linked genes rather than through disruption of a single resident gene," says CSHL Professor Michael Wigler, a pioneer in cancer genetics who participated in the research.

"The fact that the genes in 8p can cooperate to suppress tumor formation implies that the concomitant loss of multiple genes may create unexpected vulnerabilities not easily revealed through the study of single genes," states Dr. Lowe.


'/>"/>
Contact: Peter Tarr
tarr@cshl.edu
516-367-8455
Cold Spring Harbor Laboratory
Source:Eurekalert

Related biology news :

1. Improved characterization of nanoparticle clusters for EHS and biosensors research
2. New metal hydride clusters provide insights into hydrogen storage
3. NIST technique controls sizes of nanoparticle clusters for EHS studies
4. Autism Speaks responds to recent publications citing autism clusters in California
5. High red blood cell folate levels linked to silenced tumor-suppressors
6. Cancer-causing bacterium targets tumor-suppressor protein
7. LSU research finds orangutans host ancient jumping genes
8. Immune-response genes affecting breast tumor eradication
9. Geneticist develops tool to identify genes important in disease, tailoring individual treatment
10. Johns Hopkins researchers uncover genes at fault for cystic fibrosis-related intestinal obstruction
11. Scientists have discovered genes that increase the risk of osteoporosis and fractures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/7/2017)... Minn. , Feb. 7, 2017   MedNet ... supports the entire spectrum of clinical research, is pleased ... iMedNet , its innovative, highly flexible and award ... iMedNet customers. iMedNet is a proven ... provides Electronic Data Capture (EDC), but also delivers an ...
(Date:2/3/2017)... , Feb. 3, 2017 A new independent ... Strategy Partners, LLP (IdSP) . Designed to fill a ... complex identity market, founding partners Mark Crego ... combined years just in identity expertise that span federal ... non-profit leadership. The Crego-Kephart combined expertise has a common ...
(Date:1/31/2017)... , Jan. 31, 2017  Spero Therapeutics, LLC, ... for the treatment of bacterial infections, today announced ... antibacterial candidates from Pro Bono Bio Ltd (PBB) ... of multi-drug resistant forms of Gram-negative bacteria.   The ... Infectives Ltd, a PBB group company. ...
Breaking Biology News(10 mins):
(Date:2/27/2017)... Feb. 27, 2017 /PRNewswire/ - InMed Pharmaceuticals, Inc. ("InMed") (CSE: ... on Friday, February 24, 2017 a total of 10,672,750 common ... $0.13 per common share. Proceeds from the exercise of these ... InMed,s Treasury.   ... "We are grateful for this expression of confidence by ...
(Date:2/27/2017)... NEW YORK , February 27, 2017 ... up by Stock-Callers.com for evaluation today, and they are: ... ARWR), Pacific Biosciences of California Inc. (NASDAQ: PACB), and ... to an article on ETF Trends, market observers are ... Congress and administration could enact reforms to free cash ...
(Date:2/27/2017)... , Feb. 27, 2017 Fluxion Biosciences announced ... has been appointed as a Certified Service ... IsoFlux system will be used in Genetracer Biotech,s novel ... lung and colon cancer, with plans to move to ... is utilizing Fluxion,s IsoFlux System to isolate, recover, and ...
(Date:2/27/2017)... ... 27, 2017 , ... The Catalyst Midwest premix manufacturing facility has ... premix services and private label organic services. , The first organic product is Organic ... operating officer of Dynamite Marketing, which owns the facility. , Catalyst already has received ...
Breaking Biology Technology: